Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study

Table 1 The clinical characteristics between the two groups

	CC group (n = 129)	non-CC group (n = 136)	P value
Gender, n (%)			0.177
Male	84 (65.1)	99 (72.8)
Female	45 (34.9)	37 (27.2)
Age, yr			0.446
mean (SD)	57.5 (11.4)	58.5 (9.8)
Primary location, n (%)			0.812
Up	4 (3.1)	6 (4.4)
Middle	60 (46.5)	65 (47.8)
Low	65 (50.4)	65 (47.8)
Pathology, n (%)			0.996
Well differentiated	6 (4.7)	6 (4.4)
Moderately differentiated	95 (73.6)	102 (75.0)
Poorly differentiated	16 (12.4)	16 (11.8)
Others	12 (9.3)	12 (8.8)
CEA, n (%)			0.307
Normal	67 (51.9)	64 (47.1)
Unnormal	49 (38.0)	63 (46.3)
Unidentified	13 (10.1)	9 (6.6)
T stage, n (%)			0.650
< T3c	49 (38.0)	48 (35.3)
> T3b	80 (62.0)	88 (64.7)
N stage, n (%)			0.190
N0	12 (9.3)	7 (5.1)
N+	117 (90.7)	129 (94.9)
Tumor length (mm)			0.916
mean (SD)	49.0 (12.7)	49.1 (13.7)
Tumor thickness (mm)			0.838
mean (SD)	16.4 (5.0)	16.5 (7.2)
MRF, n (%)			0.501
Negative	31 (24.0)	28 (20.6)
Positive	98 (76.0)	108 (79.4)
EMVI, n (%)			0.565
Negative	44 (34.1)	51 (37.5)
Positive	85 (65.9)	85 (62.5)
Numbers of high-risk factor, n (%)			0.557
1	38 (29.5)	34 (25.0)
2	48 (37.2)	59 (43.4)
3	43 (33.3)	43 (31.6)
Interval time (d)			0.040
mean (SD)	71.7 (21.7)	76.8 (18.5)

CC: Consolidation chemotherapy; SD: Standard deviation; CEA: carcinoembryonic antigen; MRF: Mesorectal fascia; EMVI: Extralmural venous invasion.